Active, not recruitingPhase 2NCT06388941
Iptacopan in Patients With ANCA Associated Vasculitis
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Intervention
- Iptacopan(drug)
- Enrollment
- 84 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Arizona Arthritis and Rheumatology Research PLLC, Mesa, Arizona, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Northwell Health, New York, New York, United States
- Novartis Investigative Site, CABA, Buenos Aires, Argentina
- Novartis Investigative Site, La Plata, Buenos Aires, Argentina
- Novartis Investigative Site, CABA, Argentina
- Novartis Investigative Site, Concord, New South Wales, Australia
- Novartis Investigative Site, Westmead, New South Wales, Australia
- Novartis Investigative Site, Adelaide, South Australia, Australia
- Novartis Investigative Site, Clayton, Victoria, Australia
- Novartis Investigative Site, Innsbruck, Tyrol, Austria
- Novartis Investigative Site, Graz, Austria
- Novartis Investigative Site, Vienna, Austria
- Novartis Investigative Site, Leuven, Vlaams Brabant, Belgium
- Novartis Investigative Site, Roeselare, West-Vlaanderen, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06388941 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →